Cargando…
Neoadjuvant therapy for resectable pancreatic cancer
The use of neoadjuvant therapies has played a major role for borderline resectable and locally advanced pancreatic cancers (PCs). For this group of patients, preoperative chemotherapy or chemoradiation has increased the likelihood of surgery with negative resection margins and overall survival. On t...
Autores principales: | Rahman, Sheikh Hasibur, Urquhart, Robin, Molinari, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740086/ https://www.ncbi.nlm.nih.gov/pubmed/29290916 http://dx.doi.org/10.4251/wjgo.v9.i12.457 |
Ejemplares similares
-
Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021) -
Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis
por: Zhang, Hao-Qi, et al.
Publicado: (2022) -
Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021) -
Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017) -
Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma
por: Zhang, Yun, et al.
Publicado: (2021)